Aptima Combo 2® (CT/NG) Assay

A universal screening approach is needed to protect fertility

In women, 75% of chlamydia cases and 68% of gonorrhea cases are asymptomatic.1 As a result, the majority of patients are unaware that they are infected, running the risk of serious long-term health complications. Even those who are aware of their risk may not admit to being sexually active.2 Lack of screening means that roughly 30% of untreated CT infections progress to pelvic inflammatory disease (PID), while 24,000 women each year become infertile, all due to undiagnosed STIs.3,4

Improving patient care through established screening guidelines

  • National health organizations have implemented screening guidelines to address increases in CT and NG prevalence.
  • Nevertheless, screening implementation still faces multiple barriers such as lack of access, lack of awareness, and confidentiality concerns.5
  • As a result, only 52% of sexually active women ages 16-24 are screened annually for chlamydia per guidelines.6


Centers for Disease Control and Prevention7
  • Sexually active women under age 25.
  • Women age 25 and older at increased risk.
  • Those who tested positive should be retested at 3 months.


American College of Obstetrics and Gynecology8
  • Sexually active women age 25 and under.
  • Women over 25 at increased risk.


American Academy of Pediatrics9
  • Women aged 25 and younger should be tested for C. trachomatis.
  • Women younger than 25 should be tested for N. gonorrhoeae.
  • Those who tested positive should be retested at 3 months.


U.S. Preventive Services Task Force10
  • Sexually active women under age 25.
  • Older women at increased risk for infection.

A testing solution for every young woman2

Introducing a Universal Screening protocol not only helps to prevent risk of infertility due to undiagnosed infections, but also results in decreased STI prevalence and reduces total cost to patients and healthcare organizations.

Total cost for hypothetical population of 100,000 individuals (15–24 years)

Chlamydia Prevalence

Flexible testing for accessible solutions

Introducing this new protocol is easy, starting with the way you collect a sample. Specimens collected with self- and clinician-collected vaginal swabs are preferred by the CDC for CT and NG testing. It’s important to note that a pelvic exam is not required; testing may be performed with any of the following specimen types11:

  • Urine sample
  • Self- or clinician-collected swab
  • Female endocervical swab
  • Liquid-based cytology specimens
  • Male urethral swab
  • Rectal and oropharyngeal swab

In many cases, STI screening is covered by the Affordable Care Act. For patients, this may mean12:

  • No co-pay
  • No deductible
  • No out-of-pocket costs

Contact Us

We are here to support you. Have a question or need to talk to a Hologic team member?